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Partial inhibition of PI3K signaling restores VEGF-dependent activation 























PI3K suppression activates ERK signaling in synectin-deficient AECs and in zebrafish. (A–E) Western blots of AECs from WT and synectin-null 
mice after treatment with VEGF-A165 in vitro. (A) Activation of the VEGFR2 Y1175 site by VEGF-A. Data shown are for 10 minutes after VEGF 
stimulation. T-, total. (B) Time course of ERK activation after VEGF-A165 treatment. Note reduced ERK activation in synectin-deficient AECs. 
(C) Time course of Akt activation after VEGF-A165 treatment. Note reduced AKT activation in synectin-deficient AECs. (D) Restoration of ERK 
activation by PI3K inhibition. Synectin-deficient AECs were stimulated with VEGF-A in the presence of increasing concentrations of LY294002 or 
GS4898, and ERK activation was tested 10 minutes later. Note dose-dependent increase in ERK activation. (E) Time course of ERK activation in 
synectin-deficient AECs by PI3K inhibition. Note long-term restoration of activity. (F and G) Analysis of P-ERK1/2 and total ERK1/2 expression 
in zebrafish embryos. At 1-ss, embryos were injected with 12 ng anti-synectin MOs or left untreated (NT). At 8-ss, injected embryos were treated 
with 20, 50, or 100 μM GS4898 or DMSO as a control. (F) Representative Western blot. (G) Quantitative analysis of P-ERK/T-ERK ratio.
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PI3K suppression restores arterial marker expression in synectin-deficient AECs. (A) Akt1 and Akt2 knockdown in synectin-deficient AECs. 
Synectin-deficient AECs were treated with Akt1- or Akt2-specific shRNA or a control shRNA. 24 hours later, cells were subjected to Western 
blotting 10 minutes after treatment with 25 ng/ml VEGF-A165. Note activation of ERK1/2 signaling after Akt1 knockdown. (B) Expression of PI3K 
subunits p110α and p110β in synectin-deficient AECs was reduced using specific siRNA or a nonspecific sequence as a control. 24 hours later, 
the cells were treated with VEGF, and ERK activation was determined at baseline (0 minutes) or at 5 minutes. Note increased ERK1/2 activation 
in cells treated with either p110α or p110β siRNA. (C) Synectin-null (n = 6) and Ldlr–/– ApoB48-modified mice (n = 12) were treated for 3 days 
with GS4898 via an implanted Alzet minipump followed by VEGF-A injection. Shown are Western blots for hey2 and tubulin (loading control) in 
mice exposed to VEDGF alone, GS4898 alone, or a combination of both. Note decreased hey2 activation following a combination of VEGF and 
GS4898. (D) Quantitative PCR analysis of arterial marker expression. Synectin-null mice (n = 6) were treated as described above. Quantitative 
PCR was used to determine Hey2, ephrin B2, and DLL4 expression. *P < 0.05, **P < 0.01 vs. control.
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Figure 3
Functional effects of partial PI3K inhibition in synectin-deficient AECs. (A) Cell migration was assessed in the modified Boyden chamber assay. 
Synectin-deficient AECs were exposed to vehicle, 25 ng/ml VEGF-A165, 4 μM GS4898, a combination of VEGF and GS4898, or a combination 
of GS4898 and VEGF in the presence of 10 μM U0126. WT AECs were treated with either vehicle or VEGF-A165. The extent of migration is 
expressed as a ratio relative to vehicle-treated synectin-deficient AECs. Note full restoration of migration of synectin-deficient AECs exposed to 
GS4898 in the presence of VEGF. (B) 3D collagen tube branching assay. Synectin-deficient and WT AECs were placed in 3D collagen in the 
presence of 25 ng/ml VEGF, 4 μM GS4898, or both. The extent of branching was assessed 24 hours later and expressed as fold change rela-
tive to untreated control synectin-deficient AECs. Note restoration of branching in synectin-deficient AECs by GS4898 treatment. (C and D) In 
vitro Matrigel. The extent of cords branching was assessed in synectin-deficient AECs placed on growth factor–depleted Matrigel and exposed 
to 25 ng/ml VEGF-A165, 4 μM GS4898, a combination of VEGF and GS4898, or a combination of GS4898 and VEGF in the presence of 10 μM 
U0126. WT AECs exposed to VEGF were used as a control. All results are expressed relative to untreated control synectin-deficient AECs. Note 
restoration of branching in synectin-deficient AECs by GS4898 treatment. *P < 0.05, **P < 0.001 vs. control. Scale bars: 500 μm.
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ERK1/2 activation via PI3K suppression restores function of 


























ERK activation restores functional defects in synectin-
deficient AECs. (A and B) Synectin-deficient AECs were 
transduced with empty Ad vector, Ad-ME, or Ad-ME-LA. 
The transduced cells were then plated in growth factor–
depleted Matrigel and exposed to 25 ng/ml VEGF-A165 
as indicated. The extent of cord branching, assessed 
24 hours later as described in Figure 3, is expressed as 
fold change relative to untreated control synectin-deficient 
AECs. Note restoration of branching in synectin-deficient 
AECs expressing ME-LA construct. Scale bars: 500 μm. 
(C) Cell migration in modified Boyden chamber. Synec-
tin-deficient or WT AECs, treated as above, were placed 
in the chamber, and the extent of migration in response 
to VEGF was assessed. Values are expressed as fold 
change relative to that of vehicle-treated synectin-defi-
cient AECs. Note restoration of migration by the ME-LA 
construct. *P < 0.05 vs. vector control.
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Restoration of ERK1/2 activation in vivo improves angiogenesis. (A) DIVAA tubes containing vehicle control or 100 ng/ml VEGF-A with heparin 
were placed into synectin-null (n = 8) or WT (n = 8) mice. Note restoration of neovascularization in GS4898-treated synectin-null mice in the 
presence of VEGF 14 days later. (B) In vivo Matrigel plug assay. Control plugs containing no virus or VEGF, or plugs containing VEGF and 
either Ad-ME or Ad-ME-LA virus, were implanted into synectin-null mice (n = 8). Matrigel plugs containing VEGF were implanted into WT mice as 
controls (n = 8). Note extensive neovascularization in VEGF plus Ad-ME-LA plugs in synectin-null mice. (C and D) VEGF-induced VEGFR2 phos-
phorylation in Ldlr–/– ApoB48-modified mice. Ldlr–/– ApoB48-modified mice maintained for 11 weeks on either chow (n = 6) or high-fat diet (n = 6) 
were injected intraperitoneally with VEGF-A (50 ng/ml), and the extent of VEGFR2 phosphorylation (anti-Y1175 Ab) (C) and ERK1/2 phosphory-
lation (D) was assessed by Western blotting of heart (H), liver (L), and skeletal muscle (M) tissue samples. Note decreased activation of both 
VEGFR2 Y1175 and ERK1/2 in Ldlr–/– ApoB48-modified mice fed high-fat diet. (E and F) Adventitial angiogenesis assay. Ad-null control (n = 6) 
or Ad-ME-LA (n = 6) viruses in pluronic gel were added to the adventitial surface of aortas of Ldlr–/– ApoB48-modified mice fed a high-fat diet. 
Note the marked increase in neovascularization of aortas treated with Ad-ME-LA virus 21 days later. Scale bars: 10 μm. *P < 0.05 vs. control.
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Restoration of ERK1/2 activation in vivo improves arteriogenesis. (A–C) Common femoral artery ligation was carried out in synectin-null (n = 6) 
and WT (n = 6) mice as described previously (15). GS4898 was administered via the Alzet minipump. (A) Laser-Doppler analysis of blood flow 
recovery in the right foot, expressed as a ratio of blood flow in right to left foot (R/L). Synectin-null and WT mice received vehicle or GS4898. 
*P < 0.05, WT vs. synectin-null. (B) Representative μCT carried out 14 days after the arterial ligation. (C) Quantitative analysis of the μCT data in 
synectin-null mice. *P < 0.05 vs. vehicle. (D and E) Common femoral artery ligation was performed in 12 Ldlr–/– ApoB48-modified mice subjected 
to 11 weeks of high-fat diet. One group was exposed to GS4898 administered via Alzet minipumps (red bars; n = 6), while the others received 
vehicle (blue bars; n = 6). An additional group of age-matched Ldlr–/– ApoB48-modified mice was maintained on regular chow (black bars; n = 6). 
(D) Laser-Doppler analysis of blood flow, presented as flow ratios in right to left hindlimb. *P < 0.05 vs. vehicle. (E) Representative μCT images. 
Note a major increase in the arterial development in GS4898-treated mice. Scale bars: 540 μm.
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Restoration of ERK1/2 activation in vivo restores arteriogenesis in zebrafish. (A–E) Low- and high-power images of developing arterial 
vasculature in zebrafish embryos treated with vehicle (WT; A), synectin MO (B), or synectin MO plus GS4898 (C) or LY294002 (D), as 
described in Methods. Scale bars: 300 μm. (E) Quantitative analysis of ISV formation. P values vs. untreated control synectin knockdown 
are shown. (F) Effect of MEK inhibition on PI3K downregulation–induced ISV formation. Zebrafish embryos treated with vehicle or synectin 
MO were exposed to GS4898, LY294002, or 2 concentrations of U0126 as indicated. No effect on the extent of ISV formation was observed 
in WT embryos, whereas synectin MO–treated embryos exhibited complete inhibition of ISV formation. *P < 0.0001; **P = 0.0005. (G) 
Schema of PI3K/Akty1- Raf1/ER1/2 crosstalk. See text for details.
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